Preimplantation Genetic Testing Industry Overview

The global preimplantation genetic testing market size was estimated at USD 802.2 million in 2023 and is expected to grow at a CAGR of 10.3% from 2024 to 2030.

The growing prevalence of single gene, mitochondrial, and other genetic disorders is expected to drive the demand for preimplantation diagnosis and screening processes in the coming years. The Florida Department of Health reports that approximately one in every 33 babies in the U.S. is born with a congenital disability, impacting nearly 120,000 babies each year. With new tests being launched, the demand is expected to grow in coming years. For instance, in July 2023, Thermo Fisher Scientific Inc. launched 2 tests based on NGS for preimplantation genetic testing-aneuploidy (PGT-A).

Gather more insights about the market drivers, restrains and growth of the Preimplantation Genetic Testing Market

Preimplantation genetic diagnosis (PGD) is utilized prior to the IVF process to ensure a successful pregnancy. PGD is employed in IVF cycles for women who have experienced multiple miscarriages or previous pregnancies with chromosomal abnormalities. It is particularly beneficial for couples at risk of hereditary disorders, thereby positively impacting market growth.

The implementation of aneuploidy screening in PGD has significantly improved IVF procedures. Aneuploidy testing in IVF centers helps identify abnormal embryos, leading to higher pregnancy success rates. Preimplantation genetic testing for aneuploidy (PGT-A) screens embryos for chromosomal information, ensuring the correct number of chromosomes is present. The advantages of PGT-A, such as increased pregnancy chances, reduced miscarriage rates, and fewer IVF cycles needed to achieve pregnancy, are expected to boost the adoption of these tests over the forecast period.

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

• The China lung cancer screening market size was estimated at USD 505.17 million in 2023 and is projected to grow at CAGR of 11.09% from 2024 to 2030.
• The global In vitro fertilization market size was valued at USD 25.3 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 5.54% from 2024 to 2030.

Preimplantation Genetic Testing Market Segmentation

Grand View Research has segmented the global Preimplantation Genetic Testing market on the basis of procedure, product, technology, application, end use, and region:

Preimplantation Genetic Testing Procedure Outlook (Revenue, USD Million, 2018 - 2030)

• Preimplantation Genetic Screening
• Preimplantation Genetic Diagnosis

Preimplantation Genetic Testing Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagents and Consumables
• Instruments
• Software

Preimplantation Genetic Testing Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Next Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Fluorescent In-Situ Hybridization (FISH)
• Others

Preimplantation Genetic Testing Application Outlook (Revenue, USD Million, 2018 - 2030)

• Chromosomal Abnormalities
• X-linked Diseases
• Embryo Testing
• Aneuploidy Screening
• HLA Typing
• Other Applications

Preimplantation Genetic Testing End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Fertility Centers
• Hospitals
• Diagnostic Centers
• Research Centers and Academic Labs

Preimplantation Genetic Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Key Companies profiled:

• Quest Diagnostics Incorporated
• Natera, Inc.
• COOPER SURGICAL, INC.
• Genea Pty Limited.
• Invitae Corporation
• Laboratory Corporation of America Holdings
• Thermo Fisher Scientific Inc.
• Bioarray S.L.
• Illumina, Inc.
• Igenomix
• RGI
• Hoffmann-La Roche Ltd

Key Preimplantation Genetic Testing Company Insights

Some of the key players operating in the market include Quest Diagnostics Incorporated; Natera, Inc.; Illumina. Inc.

• llumina, Inc. primarily operates within the life sciences and biotechnology vertical. The company specializes in sequencing and genomics, providing advanced tools and technologies that enable researchers & professionals to analyze and decode DNA with exceptional accuracy & efficiency. Illumina’s innovations have broad applications in various industries, including healthcare, agriculture, and scientific research. It is a leading player in genomics and driving advancements in personalized medicine, genetic discovery, and more.
• Quest Diagnostics Incorporated is a publicly owned medical diagnostics company that provides clinical testing services, such as gene-based & esoteric testing, routine testing, and drugs-of-abuse testing. Its service portfolio includes anatomic pathology services & related services to healthcare providers, risk assessment services for life insurers, and others, as well as central laboratory testing for clinical trials. It has geographical presence in Mexico, India, Ireland, and the UK. Several international diagnostic laboratories, hospitals, and clinics are partners to the company.

GenEmbryomics, Color Health, Inc., and EasyDNA are some of the emerging companies in the PGT market.

• Color Health, Inc. operates in healthcare technology and genomics verticals. The company delivers healthcare solutions that focus on genetics and genomics. Color Health also offers genetic testing and counseling services, leveraging the power of genetic information to provide insights into individuals’ health risks, including hereditary conditions and cancer predispositions.
• EasyDNA primarily operates in genetic testing and diagnostics. The company offers various DNA testing services to individuals and organizations. Its services cover diverse areas, including paternity testing, ancestry & genealogy analysis, health & wellness insights, and forensic DNA testing. EasyDNA provides accessible and user-friendly testing solutions, enabling individuals to gain access to their genetic heritage, family relationships, and potential health-related factors

Recent Developments

• In January 2024, Orchid Health announced the launch of the first commercially-available whole genome sequencing service for specific diseases in preimplantation embryos.
• In July 2023, Thermo Fisher Scientific Inc. introduced 2 new NGS-based research tools designed for PGT-A. These tools are specifically intended for use in in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) procedures. The Ion ReproSeq PGT-A Kit and Ion AmpliSeq Polyploidy Kit mark the debut of research-use reproductive health assays on the Ion Torrent Genexus Integrated Sequencer.

Order a free sample PDF of the Preimplantation Genetic Testing Market Intelligence Study, published by Grand View Research.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.